Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs

AIDS

Volumn 14, Issue 6, 2000, Pages 659-669

  Fraser, Christophe ^a   Ferguson, Neil M ^b   Ghani, Azra C ^b   Prins, Jan M ^b   Lange, Joep M A ^b   Goudsmit, Jaap ^b   Anderson, Roy M ^b   De Wolf, Frank ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

Activation; Antiretroviral therapy; Homeostasis; Immune based therapy; Mathematical models

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; HYDROXYUREA; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; NEVIRAPINE; OKT 3; RITONAVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG POTENCY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOTHERAPY; LYMPH NODE CELL; MATHEMATICAL MODEL; MONONUCLEAR CELL; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HOMEOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MODELS, BIOLOGICAL; MUROMONAB-CD3; RECOMBINANT PROTEINS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 0034052614     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200004140-00005     Document Type: Article

References (65)

1. 1. Wei XP, Ghosh SK, Taylor ME, et al. Viral dynamics in human-immunodeficiency-virus type-1 infection. Nature 1995, 373:117-122.
2. 2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
3. 3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
4. 4. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
5. 5. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
6. 6. Pakker NG, Notermans DW, deBoer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
7. 7. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338: 853-860.
8. 8. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
9. 9. Perelson AS, Essunger P, Cao YZ, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
10. 10. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197.
11. 11. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
12. 12. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
13. 13. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
14. 14. Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell 1998 93:665-671.
15. 15. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
16. 16. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
17. 17. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Natre Med 1999, 5:512-517.
18. 18. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
19. 19. Ho DD. Toward HIV eradication or remission: The tasks ahead. Science 1998, 280:1866-1867.
20. 20. Cohen J. AIDS therapies - Exploring how to get at and eradicate hidden HIV. Science 1998, 279:1854-1855.
21. 21. Chatenoud L, Ferran C, Legendre C, et al.: In vivo cell activation following OKT3 administration - systemic cytokine release and modulation by corticosteroids. Transplantation 1990, 49:697-702.
22. 22. Ellenhorn JDI, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA. Activation of human T-cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990, 50:608-612.
23. 23. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331-340.
24. 24. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998, 188:83-91.
25. 25. Prins JM, Juriaans S, van Praag RME, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1 infected patients on potent anti-retroviral therapy. AIDS 1999, 13:2405-2410.
26. 26. DePaoli P, Zanussi S, Simonelli C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV plus subjects. J Clin Invest 1997, 100:2737-2743.
27. 27. Simonelli C, Zanussi S, Comar M, et al. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia. AIDS 1998, 12:112-113.
28. 28. Simonelli C, Zanussi S, Sandri S, et al. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:20-27.
29. 29. Zanussi S, Simonelli C, Bortolin MT et al. Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients. AIDS Res Human Retroviruses 1999, 15:97-103.
30. 30. Weverling GJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-F122.
31. 31. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989, 47:606-608.
32. 32. Muller TF, Grebe SO, Neumann MC, et al. Persistent long-term challenges in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997, 64:1432-1437.
33. 33. Buysmann S, Bemelman FJ, Schellekens PTA, vanKooyk Y, Figdor CG, tenBerge IJM. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996, 87: 404-411.
34. 34. Margolick JB, Donnenberg AD, Munoz A, et al. Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3-populations suggest regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993, 6: 153-161.
35. 35. Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection. J Acquir Immune Defic Syndr 1993, 6:144-152.
36. 36. Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nature Med 1995, 1:674-680.
37. 37. Adleman LM, Wofsy D. Blind T-cell homeostasis in CD4-deficient mice. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:334-340.
38. 38. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 -infected humans. Nature Med 1999, 5:83-89.
39. 39. Whitmire JK, Asano MS, MuraliKrishna K, Suresh M, Ahmed R. Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection. J Virol 1998, 72:8281-8288.
40. 40. Maini MK, Casorati G, Dellabona P, Wack A, Beverly PCL. T-cell clonality in immune responses. Immunol Today 1999, 20: 262-266.
41. 41. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997, 89:3700-3707.
42. 42. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T-lymphocytes with intermittent courses of interleukin-2 in patients with human-immunodeficiency-virus infection - a preliminary study. N Engl J Med 1995, 332:567-575.
43. 43. Davey RT, Jr., Chaitt DG, Albert JM, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999, 179:849-858.
44. 44. Hengge UR, Goos M, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998, 12:F225-F234.
45. 45. Zou W, Foussat A, Houhou S, et al. Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. AIDS 1999, 13:455-463.
46. 46. Chun T-W, Engel D, Mizell SB, et al. Effect of interleukin-2 on the a pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nature Med 1999, 5:651-655.
47. 47. Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤ 250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999, 180:56-60.
48. 48. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996, 174:1191-1199.
49. 49. Cheeseman SH, Davaro RE, Ellison RT. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996, 334:1272.
50. 50. Fowke KR, Damico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1 -infected patients. AIDS 1997, 11:1013-1021.
51. 51. Goletti D, Weissman D, Jackson RW, et al. Effect of mycobacterium tuberculosis on HIV replication - role of immune activation. J Immunol 1996, 157:1271-1278.
52. 52. Ho DD. HIV-1 Viremia and influenza. Lancet 1992, 339:1549.
53. 53. Ortigao de Sampaio MB, Shattock RJ, Hayes P, et al. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS 1998, 12:F145-F150.
54. 54. Ostrowski MA, Krakauer DC, Li YX, et al. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 1998, 72:7772-7784.
55. 55. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
56. 56. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus-replication after vaccination of HIV-1-infected individuals. J Exp Med 1995, 182:1727-1737.
57. 57. Vigano A, Bricalli D, Trabattoni D, et al. Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. AIDS Res Hum Retroviruses 1998, 14:727-734.
58. 58. Ferguson NM, de Wolf F, Ghani AC, et al. Antigen driven CD4+ T-cell and HIV-1 dynamics: Residual viral replication under HAART. Proc Nalt Acad Sci 1999, 96:15167-15172.
59. 59. Bukrinsky MI, Haffar OK. HIV-1 nuclear import: in search of a leader. Front Biosci 1997, 2:d578-d587.
60. 60. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990, 9:1551-1560.
61. 61. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990, 61:213-222.
62. 62. Stevenson M. Molecular mechanisms for the regulation of HIV replication, persistence and latency. AIDS 1997, 11 (suppl A):S25-S33.
63. 63. Brinkman K, Huysmans F, Galama JMD, Boucher CAB. In-vivo anti-CD3-induced HIV-1 viraemia. Lancet 1998, 352:1446.
64. 64. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press; 1991.
65. 65. Cooper DA, Emery S. Latent reservoirs of HIV infection: Flushing with IL-2? Nature Med 1999, 5:611-612.